# CJC-1295 References: The Cited Studies, Trials, and Regulatory Sources

> CJC-1295 references — the full citation register behind this site: the human PK studies, rat bioconjugate work, the discontinued trial, and the FDA and WADA sources.

The complete citation register — peer-reviewed studies, the clinical-trial registry entry, and the regulatory briefing materials behind every claim on the site.

## How to read this register

These are the CJC-1295 references cited across the site, numbered to match the inline markers on each page. The core human pharmacokinetic record is references 1 and 3; the foundational rat bioconjugate work is reference 2; the regulatory and anti-doping sources are references 6, 7, and 10. Each entry carries a DOI or a PubMed/registry link so the original can be read in full.

The register is deliberately compact. The published human evidence base for CJC-1295 is small, and this site cites it directly rather than padding the list — every numbered source below is one a reader can open and check.

## References

[1] Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. https://pubmed.ncbi.nlm.nih.gov/16352683/
[2] Jette L, Leger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-3058. https://pubmed.ncbi.nlm.nih.gov/15817669/
[3] Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-4797. https://pubmed.ncbi.nlm.nih.gov/17018654/
[4] Alba M, Fintini D, Sagazio A, Lawrence B, Castaigne JP, Frohman LA, Salvatori R. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006;291(6):E1290-E1294. https://pubmed.ncbi.nlm.nih.gov/16822960/
[5] Sackmann-Sala L, Ding J, Frohman LA, Kopchick JJ. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Horm IGF Res. 2009;19(6):471-477. https://pubmed.ncbi.nlm.nih.gov/19386527/
[6] Henninge J, Pepaj M, Hullstein I, Hemmersbach P. Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug Test Anal. 2010;2(11-12):647-650. https://doi.org/10.1002/dta.233
[7] ConjuChem Inc. A study to evaluate CJC-1295 in HIV patients with visceral obesity. ClinicalTrials.gov identifier NCT00267527. 2006. https://clinicaltrials.gov/study/NCT00267527
[8] Modified GRF (1-29): chemical and pharmacological description (encyclopedic reference; research-handling and community-protocol context). 2024. https://en.wikipedia.org/wiki/Modified_GRF_(1-29)
[9] Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet. 2004;363(9418):1346-1353. https://pubmed.ncbi.nlm.nih.gov/15110491/
[10] U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee (PCAC) meeting briefing document on growth hormone secretagogues (CJC-1295). FDA Advisory Committee Briefing Materials. 2024. https://www.fda.gov/media/183819/download
[11] Modified GRF (1-29): synthetic GHRH(1-29) analog with four stabilizing substitutions and no albumin-binding DAC moiety (short-acting no-DAC form; distinguished from CJC-1295 DAC). Encyclopedic reference. 2024. https://en.wikipedia.org/wiki/Modified_GRF_(1-29)
[12] Granata R, Leone S, Zhang X, Gesmundo I, et al. Growth hormone-releasing hormone and its analogues in health and disease. Nat Rev Endocrinol. 2025;21(3):180-195. https://pubmed.ncbi.nlm.nih.gov/39537825/
[13] The development of growth hormone-releasing hormone analogs: therapeutic advances in cancer, regenerative medicine, and metabolic disease. Rev Endocr Metab Disord. 2024. https://pubmed.ncbi.nlm.nih.gov/39592529/

---

An instrument-cluster reading of the CJC-1295 record — the established pharmacokinetics lit in cyan, the unapproved status and missing human data flagged in amber and red, with no clinic behind the console and nothing here prescribed or sold.